Placebo News and Research

RSS

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.

12 Nov 2013

Peripheral prism glasses provide simple mobility rehabilitation intervention for hemianopia

More than a million Americans suffer from hemianopia, or blindness in one half of the visual field in both eyes as the result of strokes, tumors or trauma. People with hemianopia frequently bump into walls, trip over objects, or walk into people on the side where the visual field is missing.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

Aptiom receives FDA approval to treat seizures associated with epilepsy

The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.

10 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

$Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D$

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

A recent prospective, randomized, placebo-controlled clinical trial reports that calcium and vitamin D supplementation improves bone density in a group of male veterans with epilepsy who were treated chronically with antiepileptic drugs.

8 Nov 2013

Vitamin C can improve skeletal muscle fatigue in COPD patients

Chronic obstructive pulmonary disease—a health problem in which the lungs lose their inherent springiness, making it progressively harder to breathe—can have a dramatic effect on the ability to exercise and even perform simple activities of daily life because of the disease's fallout effects on skeletal muscles.

8 Nov 2013

Vitamin D and calcium improves bone density in male veterans treated with AEDs

8 Nov 2013

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.

7 Nov 2013

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Boehringer Ingelheim and Eli Lilly and Company announce new data that reinforce the efficacy and tolerability of linagliptin in people with Type 2 Diabetes and liver disease, as well as Asian people with T2D aged 65 years or older.

7 Nov 2013

Natura Therapeutics’ natural dietary intervention improves older adults' cognitive functioning

A human clinical study of older adults has demonstrated that participants who took NutraStem Cardio-, a natural dietary supplement created by Natura Therapeutics, Inc., showed a significant increase in cognition when compared to age-matched individuals taking a placebo.

7 Nov 2013

Tea helps promote weight loss and improve bone health

Decades worth of research shows that tea-the second most consumed beverage in the world-may help prevent chronic illnesses, including heart disease, certain types of cancer and type 2 diabetes. New research shows tea has been found to help promote weight loss and maintain a healthy weight, improve bone health and activate areas of the brain that bolster attention, problem solving and mood.

7 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has completed its efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy.

5 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Magnesium deficiency may play important role in cognitive impairment

November is National Alzheimer's Awareness Month and the serious issues of cognitive health will be in the spotlight in the coming weeks. The medical community agrees that cognitive impairment, ranging from mild to severe, is almost epidemic in the U.S. as the Baby Boomer generation is aging and living longer. Scientists believe one reason is that the human brain begins shrinking after age 25. Structural changes and loss of brain synapses lead to rapid decline in cognitive health.

5 Nov 2013

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a 150-patient randomized, placebo-controlled, double blind clinical trial conducted by scientists at The Scripps Research Institute.

4 Nov 2013

Placebo News and Research

Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study

Peripheral prism glasses provide simple mobility rehabilitation intervention for hemianopia

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Aptiom receives FDA approval to treat seizures associated with epilepsy

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Risedronate may help prevent new vertebral fractures when taken with calcium and vitamin D

Vitamin C can improve skeletal muscle fatigue in COPD patients

Vitamin D and calcium improves bone density in male veterans treated with AEDs

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Linagliptin shows efficacy, tolerability in adults with T2D and liver disease

Natura Therapeutics’ natural dietary intervention improves older adults' cognitive functioning

Tea helps promote weight loss and improve bone health

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Trophos completes efficacy study of olesoxime in patients with Spinal Muscular Atrophy

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Magnesium deficiency may play important role in cognitive impairment

Generic drug gabapentin appears to be safe, effective in treating alcohol dependence

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News